Compugen Ltd (CGEN) Stock Price, Quote & News

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 765 8585

Fax: 972 3 765 8555

Website: cgen.com

Address:

Azrieli Center, Building D 26 Harokmim Street, Holon, Israel

WarpedHitbox Jan. 17 at 12:58 AM

~ @CoralSharkie different different 🥶 ~Elite mindset. Elite value. ~If you’re not tapped in, you’re late. One follow = free game. $CLYM $BGMS $CGEN $INAB {][] On watxh as well.

0 · Reply

dup007 Jan. 16 at 5:19 PM

$CGEN Up up and away

0 · Reply

Dewjek59 Jan. 16 at 1:54 PM

$CGEN Tons of resistance here. Needs to get past $2.65 then $3.05 to be set free. Let's

1 · Reply

Safran18 Jan. 16 at 12:48 PM

$CGEN I always wondered how a legit great company stay so beaten down so long .. while so many scams get pumped hundreds or even thousand percent when filing some news like hiring two Sales persons in Alaska .. This stock should be 7$ !! And stay there before next leg up

1 · Reply

John_McClane911 Jan. 15 at 10:47 PM

$CGEN Stay over 2, baby! You can do this.

0 · Reply

TwitteringTom Jan. 15 at 9:19 PM

$CGEN what was that end of session dip!

1 · Reply

www_larval_com Jan. 15 at 8:57 PM

$BNKK -5%[46%] $CGEN -4%[7%] $MLEC -4%[110%] $BGL 3%[-15%] $CNSP 3%[19%] most notable movement into the final minutes of trading.

0 · Reply

HuntingBenjmins Jan. 15 at 6:41 PM

$CGEN a 50% bump in two weeks? I approve.

0 · Reply

John_McClane911 Jan. 15 at 5:37 PM

$CGEN Good company.

1 · Reply

Otus Jan. 15 at 5:33 PM

$CGEN apparently Cathy Woods and Ark are back in.

1 · Reply

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Nov 10, 2025, 10:51 AM EST - 2 months ago

Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:00 AM EST - 2 months ago

Compugen Reports Third Quarter 2025 Results

Nov 4, 2025, 7:00 AM EST - 2 months ago

Compugen to Participate in Stifel 2025 Healthcare Conference

Oct 27, 2025, 7:00 AM EDT - 2 months ago

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Oct 13, 2025, 7:00 AM EDT - 3 months ago

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Oct 6, 2025, 7:00 AM EDT - 3 months ago

Compugen to Present at SITC 2025

Sep 8, 2025, 7:00 AM EDT - 4 months ago

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Aug 28, 2025, 7:00 AM EDT - 5 months ago

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 8, 2025, 5:13 AM EDT - 5 months ago

Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Aug 7, 2025, 6:30 AM EDT - 5 months ago

Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 5 months ago

Compugen Reports Second Quarter 2025 Results

Jul 28, 2025, 7:00 AM EDT - 6 months ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 23, 2025, 7:00 AM EDT - 6 months ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Jul 21, 2025, 7:00 AM EDT - 6 months ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jun 12, 2025, 7:00 AM EDT - 7 months ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

May 19, 2025, 10:21 AM EDT - 8 months ago

Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript

May 19, 2025, 7:00 AM EDT - 8 months ago

Compugen Reports First Quarter 2025 Results

May 13, 2025, 7:00 AM EDT - 8 months ago

Compugen Announces Leadership Transitions Effective September 2025

May 5, 2025, 7:00 AM EDT - 9 months ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Mar 26, 2025, 7:00 AM EDT - 10 months ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 4, 2025, 10:34 AM EST - 11 months ago

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 7:00 AM EST - 11 months ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 3, 2025, 7:00 AM EST - 11 months ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 11 months ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 18, 2025, 7:00 AM EST - 11 months ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 18, 2025, 6:11 AM EST - 11 months ago

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Feb 4, 2025, 7:00 AM EST - 1 year ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 1 year ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 12, 2024, 3:35 PM EST - 1 year ago

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2024 Results

Nov 11, 2024, 7:00 AM EST - 1 year ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 1 year ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 10, 2024, 5:54 AM EDT - 1 year ago

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports Second Quarter 2024 Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jun 17, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Upcoming Antibody Industrial Symposium

May 30, 2024, 7:00 AM EDT - 1 year ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

May 20, 2024, 12:22 PM EDT - 1 year ago

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript

May 20, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2024 Results

May 16, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 15, 2024, 7:00 AM EDT - 1 year ago

Compugen Appoints David Silberman as Chief Financial Officer

May 6, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

WarpedHitbox Jan. 17 at 12:58 AM

~ @CoralSharkie different different 🥶 ~Elite mindset. Elite value. ~If you’re not tapped in, you’re late. One follow = free game. $CLYM $BGMS $CGEN $INAB {][] On watxh as well.

0 · Reply

dup007 Jan. 16 at 5:19 PM

$CGEN Up up and away

0 · Reply

Dewjek59 Jan. 16 at 1:54 PM

$CGEN Tons of resistance here. Needs to get past $2.65 then $3.05 to be set free. Let's

1 · Reply

Safran18 Jan. 16 at 12:48 PM

1 · Reply

John_McClane911 Jan. 15 at 10:47 PM

$CGEN Stay over 2, baby! You can do this.

0 · Reply

TwitteringTom Jan. 15 at 9:19 PM

$CGEN what was that end of session dip!

1 · Reply

www_larval_com Jan. 15 at 8:57 PM

$BNKK -5%[46%] $CGEN -4%[7%] $MLEC -4%[110%] $BGL 3%[-15%] $CNSP 3%[19%] most notable movement into the final minutes of trading.

0 · Reply

HuntingBenjmins Jan. 15 at 6:41 PM

$CGEN a 50% bump in two weeks? I approve.

0 · Reply

John_McClane911 Jan. 15 at 5:37 PM

$CGEN Good company.

1 · Reply

Otus Jan. 15 at 5:33 PM

$CGEN apparently Cathy Woods and Ark are back in.

1 · Reply

HuntingBenjmins Jan. 15 at 3:40 PM

$CGEN This will certainly make it on to some traders radars. Can’t deny this momentum.

1 · Reply

TwitteringTom Jan. 15 at 3:26 PM

$CGEN

0 · Reply

John_McClane911 Jan. 14 at 6:42 PM

$CGEN https://www.youtube.com/watch?v=LQUXuQ6Zd9w&list=RDLQUXuQ6Zd9w&start_radio=1

0 · Reply

Otus Jan. 14 at 5:42 PM

$CGEN really needs to get over that 2 hump and stay there. If this happens I’d be very bullish short term. If it doesn’t happen I think we will be range bound until something new occurs. Still very bullish long term.

0 · Reply

John_McClane911 Jan. 12 at 10:08 PM

$CGEN 🤫 https://www.youtube.com/watch?v=htobTBlCvUU&list=RDhtobTBlCvUU&start_radio=1

0 · Reply

wenmoon_stonks Jan. 12 at 7:44 PM

$CGEN another update on high volume. Let's moon 🚀 🚀 🚀 🚀

0 · Reply

lindakooy Jan. 11 at 1:38 PM

$CGEN interesting

0 · Reply

Equities141 Jan. 10 at 12:32 AM

$CGEN we are closer than we have ever been.

1 · Reply

Equities141 Jan. 9 at 8:31 PM

$CGEN You are gonna regret sayung that. Only someone that cant see past their eyelids would not see the value in CGEN.

1 · Reply

Equities141 Jan. 9 at 8:29 PM

$CGEN CGEN IS THE DIAMOND IN THE RUFF. Their TGIT works!!! That makes them so much more valuable. Their advanced payment from Astrozenica proves that they know Compugen is the magic sauce.

1 · Reply

HuntingBenjmins Jan. 9 at 8:18 PM

$CGEN About time this thing gets some respect. No debt. Solid financials.

0 · Reply

John_McClane911 Jan. 9 at 3:01 PM

$CGEN 🤫I think the management is also interested in moving the stock higher than it is at the moment. 🤫

0 · Reply

Market Cap	176.70M
Revenue (ttm)	27.86M
Net Income (ttm)	-14.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-51.08%
Debt to Equity Ratio	0.00

Volume	1,059,600
Avg Vol	440,106
Day's Range	N/A - N/A
Shares Out	89.24M
Stochastic %K	75%
Beta	2.85
Analysts	Strong Sell
Price Target	$5.80